Home › Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
 

Keywords :   


Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet

2016-04-12 23:00:22| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Mercks house dust mite sublingual allergy immunotherapy (SLIT) tablet. Language: English read more

Tags: house application license acceptance

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
14.05Growth Opportunities for Health and Beauty Care Revenue in Grocery Stores
14.05SONGWON Announces 1Q 2024 Financial Results
14.05Tesco chief's pay more than doubles to 10m
14.05Evonik Receives the Trade Excellence Award in Alabama
14.05My emails look ludicrous, says ex-Post Office PR boss
14.05Feedworks USA grows its monogastric team
14.05Polyart to market full range of services under PolyServices brand
14.05Nilpeter partners with B&R for advanced vision system
More »